The WHO will take a call on issuing a 'Global Medical Products Alert' on the cough syrup, Coldrif, after receiving an official confirmation from authorities here. The agency issues such alerts for substandard and contaminated medicines.
India's drug regulator CDSCO has recalled three cough syrups and halted their production after the WHO raised concerns about potential contamination and links to child deaths. The WHO is investigating reports of pediatric illnesses and deaths in India potentially linked to contaminated syrups.
FDC drugs are those which contain a combination of two or more active pharmaceutical ingredients in a fixed ratio and are also referred to as 'cocktail' drugs.
Actor Allu Arjun and makers of the film Pushpa on Wednesday announced financial assistance of Rs 2 crore for the family of the woman who died in a stampede during the film's screening at a theatre in Hyderabad on December 4.
Telugu actor Allu Arjun visited the boy who was seriously injured in a stampede at the premiere of his film 'Pushpa 2'. The actor is an accused in the case filed after a woman died and her son was injured in the incident. Allu Arjun was accompanied by Telangana State Film Development Corporation Chairman Dil Raju during his visit. The actor had previously expressed concern over the boy's well-being and had wished for his speedy recovery.
Declaring the Telangana government's support to the Telugu film industry, Chief Minister A Revanth Reddy on Thursday said the former would take steps to make Hyderabad a destination for international film shootings.
The eight-year-old boy, who was injured in the stampede during the screening of Pushpa-2 in Hyderabad on December 4, was taken off oxygen and ventilator support as his condition is improving, his father has said.
Among the commonly used analgesic formulations (painkillers) found NSQ are combinations of paracetamol with ibuprofen, diclofenac and mefenamic acid. Medications using these combinations are commonly used to treat fever, mild migraine, period and muscle pain.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
'The simultaneous fire from so many guns rained down on the enemy and pulverised them, a sight I can never forget till my last breath.'
Some of the popular brands that would be impacted include Phensedyl (Abbott), Tixylix (Abbott), Gluconorm PG (Lupin), Ascoril D (Glenmark), Solvin Cold (Ipca), D Cold Total (Paras Pharma).
Few drugs in the market are not approved by the authorities and can be life-threatening.
Govt bans brands with annual sales worth Rs 3,728 crore.
Justice Rajiv Sahai Endlaw allowed 454 petitions moved by various pharma and healthcare majors, like Pfizer, Glenmark, Procter and Gamble and Cipla, challenging the government's March 10 notification banning the FDCs, saying the decision was taken by the Centre without following procedure prescribed in the Drugs and Cosmetics Act.
What has worked though for Brand Saridon has been its single-minded focus on headaches as opposed to other analgesics that dwell on a wider set of problems, reports Sohini Das.
It also comes ahead of a possible visit by President Donald Trump to India later this month. Trump is set to visit India on a two-day trip between February 23 and 26 and both sides are in the process of fine-tuning his schedule, according to sources in New Delhi.
The original list had named 349 drugs, but 15 drugs, approved prior to 1988, have been kept outside the purview of the ban
The gap between stand-alone Indian figures and global figures can be the difference between sell and buy.
The matter is now expected to be raised with the PMO.
The Delhi high court had earlier allowed Indian pharma major Wockhardt to sell its Ace Proxyvon tablets, which is a mixture of three salts -- aceclofenac, paracetamol and rabeprazol -- a combination that is banned.
It is the fundamentals of companies that will drive stock performance.
Gains were led by Tata Motors amid robust sales in June along with select financials.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances